Optimizing the method for authenticating pharmaceutical products of different dosage forms using dual laser handheld raman spectroscopy by Assi, S & Fortunato, L
 Assi, S and Fortunato, L
 Optimizing the method for authenticating pharmaceutical products of different 
dosage forms using dual laser handheld raman spectroscopy
http://researchonline.ljmu.ac.uk/id/eprint/13852/
Article
LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Assi, S and Fortunato, L (2017) Optimizing the method for authenticating 
pharmaceutical products of different dosage forms using dual laser 




Optimising the method for authenticating pharmaceutical products 
of different dosage forms using dual laser handheld Raman 
spectroscopy 
 
Sulaf Assi and Louise Fortunato 
Faculty of Science and Technology, Bournemouth University, 





Handheld Raman spectroscopy have emerged over the last few years as a rapid 
technique for authenticating medicines. Major challenges arose in the authentication 
process attributed to the Raman activity of the main constituents or to the formulation 
type. This witnessed the masking of the Raman signal of herbal medicinal products or 
medicinal products of low dosage forms. Liquid and semisolids formulations 
represented a further challenge in the authentication process which was mainly 
attributed to the number of soluble/insoluble constituents. The present work aims to 
optimise the method for authenticating medicinal products of different dosage forms 
using dual laser handheld Raman spectroscopy. 
 
Introduction 
Medicine authentication is a complex process that takes into account not only the 
chemical signature of the medicine but also its physical properties [1]. Handheld 
Raman spectroscopy have emerged over the last few years as a quick tool for 
authenticating medicines and related formulations [2-5]. Many factors have 
contributed to the efficiency of handheld Raman and were mainly associated with the 
flexibility of the technique in relation to the user and analyte. For users, Raman 
spectroscopy offers portability, flexibility and ease of analysis. Handheld Raman 
instruments offer portability as they can be carried out in the field to the sample 
location. In the field, handheld Raman instruments operate over a wide temperature 
range of -5C to +40C without the need for power supply (battery life-time around 4-
8 hours). They are equipped with inbuilt identification algorithms that give instant 
yes/no answer. Nonetheless, the results can be exported after measurement to a 
computer for offline analysis [6-8]. 
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In relation to the analyte, handheld Raman spectroscopy surpassed other 
spectroscopic characterisation techniques as it showed to be: (1) non-destructive in 
contrary to attenuated total reflectance-Fourier transform infrared (ATR-FTIR) that 
required crushing tablets, (2) gives specific chemical signatures to the analyte(s) of 
interest, (3) Raman signatures are seen regardless of the physical state of analyte 
(solid, liquid, semi-solid, etc..), (4) water does not interfere with the Raman signature 
of liquids [9].  
Nonetheless, the majority of handheld Raman authentication studies were conducted 
on solid formulations being tablets or powders; with very few studies focusing on 
liquids [5-13]. This was mainly attributed to the low amounts of active pharmaceutical 
ingredients (APIs) present in liquid formulations, the presence of multiple Raman 
inactive excipients which fluoresce and mask the Raman signatures, and the fact that 
most handheld instruments operate over the range of 250-2000 cm-1 missing the water 
peaks around 3000 cm-1. Handheld Dual laser Raman equipped with SSE can 
overcome these disadvantages as it overcome both fluorescence caused by 
constituents of low Raman activity, and operate over a wide wavenumber range of 
300-3200 cm-1 [14,15]. Therefore, this work aims to utilise handheld dual laser Raman 
spectroscopy for authenticating medicines of different dosage forms. 
 
Methods 
Different formulations of active pharmaceutical ingredients, excipients and medicinal 
products were included in this study, being: powders, tablets, capsules, liquids and 
semi-solids. For powder formulations: one API (sildenafil citrate) and six different 
excipients were obtained from Chemical suppliers: lactose, magnesium stearate, 
microcrystalline cellulose, sodium carboxymethylcellulose, sucrose and titanium 
dioxide. Three different tablet formulations were used and included medicines 
containing paracetamol, clopidogrel, and levothyroxine. Two capsule formulations 
were used, one containing orlistat and the second sibutramine. Liquid formulations 
used included antihistamines, cough syrups and emollients. Additionally, anti-
inflammatory and antihistamine creams were included.  
The aforementioned formulations were measured using a dual laser handheld Raman 
instrument equipped with two different sample holders for both tablets and vials. 
Spectra of tablets were collected from both sides with no sample preparation. Liquids, 
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powders, gels and capsule contents were emptied into glass vials and multiple spectra 
were measured through glass vials.  
The Raman method was optimised taking into account the following parameters: the 
instrument position, sample holder, number of scans per spectrum, number of spectra 
per sample and accuracy of identification method. Spectral analysis was conducted 
using OPUS software and Matlab 2014b. Spectral quality was evaluated by taking into 
account the spectral integration time, range of scattering, scattering intensities and 
signal to noise (S/N) ratio. For authentication, two identification algorithms were 
evaluated being: correlation in wavenumber space (CWS) and principal component 
analysis (PCA). CWS algorithm evaluated the correlation coefficient (r) value between 
the test and reference spectrum. The threshold taken for r values was 0.95 [8]. 
 
Results and Discussion 
Spectral quality 
Powders and tablets showed better spectral quality than capsules, gels and liquids, 
when the four variables were taken into account being: exposure time, number of 
peaks, maximum intensities and S/N. Powders and tablets showed lower exposure 
times, more peaks and higher S/N compared to other formulations. 
 
Powders 
Excipients showed better-quality signal when measured through the vial holder. The 
exposure time and number of scans depended on the Raman activity of the individual 
substances. It is noteworthy to mention that none of the excipients showed weak 
Raman signatures and their Raman spectra were generated in less than three 
seconds (Table 1).  
 
Table 1. Spectral quality of the excipients and medicines measured. 
Sample Exposure  
time 
(seconds) 
Nscans Npeaks Maximum  
intensity 
S/N Raman  
activity 
Powders 
Lactose 2.7 2 30 20356 10.6 M 
Magnesium stearate 1.65 2 11 13161.6 6.3 M 
Microcrystalline  
cellulose 
2 3 16 5568 7.7 M 




2.5 3 17 6147.9 2.4 M 
Titanium dioxide 0.5 1 3 24415.4 3 S 
Tablets 
ClopidogrelB1 0.25 3 8 2706.7 8.24 M 
ClopidogrelB2 0.25 3 8 3526 29.9 S 
ClopidogrelB3 0.23 3 12 2684.9 2.57 M 
ClopidogrelB4 0.75 1 12 5082.2 11.9 W 
ClopidogrelB5 0.22 4 8 2749.3 10.5 M 
ClopidogrelB6 0.75 1 12 4919.3 3.85 W 
LevothyroxineB1 0.73 2 27 7058.2 8.8 M 
LevothyroxineB2 0.73 2 27 7102.1 13.7 M 
LevothyroxineB3 0.69 2 27 7023.6 13.6 M 
LevothyroxineB4 0.71 2 27 7127.4 22.7 S 
Capsules 
OrlistatB1 1.5 2 25 13234.2 2.82 M 
OrlistatB2 1.5 2 25 12263.7 2.85 M 
OrlistatB3 1.5 2 25 13665.9 2.83 M 
OrlistatB4 1.5 2 25 10833.9 2.49 M 
OrlistatB5 1.5 2 25 10943.6 2.43 M 
OrlistatB6 1.5 2 25 13271.1 1.95 M 
SibutramineB1 1.4 2 31 9342.3 10.7 S 
SibutramineB2 1.4 2 31 9134.3 10.9 S 
SibutramineB3 1.4 2 31 9269.9 16.4 S 
SibutramineB4 1.4 2 31 9646.9 16.9 S 
SibutramineB5 1.4 2 31 9600.7 13.2 S 
SibutramineB6 1.4 2 31 9916.6 16.5 S 
Gels 
ibuprofen B1 2.1 2 8 3712.6 0.76 W 
ibuprofen B2 1.8 2 12 3701.6 8.28 W 
ibuprofen B3 3.1 3 10 3686.3 1.2 W 
diclofenac B1 0.8 2 17 2899.8 27.5 M 
diclofenac B2 0.72 2 13 2333.5 2.41 W 
diclofenac B3 0.41 2 20 3821 3.01 W 
diclofenac B4 0.25 2 21 3364.5 3.63 W 
diclofenac B5 2.67 2 11 6278.9 5.7 W 
Liquids 
Cough mixture B1 3.1 3 9 5808.3 5.91 W 
Cough mixture B2 2.5 2 16 5101.6 8.32 W 
Cough mixture B3 1.7 4 18 15352 24.4 M 
B: batch, S: strong, M: medium, Nscans: number of scans per spectrum, Npeaks: number of peaks, S/N: signal to noise ration, 
W: weak, Clopidogrel B4 and B6 are counterfeit batches. 
 
The Raman activity of the measured excipients was of medium or strong activity. 
Titanium dioxide signature required the minimum time (of 0.5 seconds) and this is 
attributed to its strong Raman activity [16]. This was followed by sucrose and 
magnesium stearate which needed 0.7 and 1.65 seconds respectively. 
Microcrystalline cellulose, sodium carboxymethylcellulose and lactose required 
between two and three seconds. Apart from titanium dioxide, 2-3 scans were enough 
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to get a clear Raman signature for the excipients. The number of peaks per spectrum 
of the aforementioned excipients ranged between 11 (observed for magnesium 
stearate) and 33 (observed for sucrose). Microcrystalline cellulose and sodium 
carboxymethylcellulose showed 16 and 17 peaks respectively. Lactose showed 
numerous peaks (n = 30), which is ideal for material characterisation. Furthermore, 
the six excipients showed variable Raman intensities and the increase in intensity was 
associated with the Raman activity of the excipient measured with the exception of 
titanium dioxide (Figure 1).  
 
 
Figure 1. Raw Raman spectra of (a) lactose, (b) magnesium stearate, (c) 
microcrystalline cellulose, (d) sucrose, (e) sodium carboxymethylcellulose and 
(f) titanium dioxide measured using a handheld dual laser Raman spectrometer. 
 
Lactose showed high scattering intensity of 20356 arbitrary units and high S/N (10.6). 
This was followed by magnesium stearate which showed scattering intensity of 
13161.6 arbitrary units. In addition, sucrose, microcrystalline cellulose and sodium 
carboxymethylcellulose showed scattering intensities of 2461.9, 5568 and 6147.9 
arbitrary units, and S/N of 4.87, 7.7 and 2.4 respectively. Yet all the aforementioned 
substances showed significant scattering over the full wavenumber range between 
300 and 3200 cm-1 which allowed their characterisation. Titanium dioxide showed a 
maximum scattering intensity of 24415.4 arbitrary units at 638 cm-1; yet, this increase 
was associated with increased noise (S/N = 3). This could be partly due to the low 
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exposure time for titanium dioxide (one scan over 0.5 seconds). Increasing the 
exposure time of titanium dioxide resulted in saturating the Raman signal [16].  
 
Tablets 
There were no significant differences between spectra collected from both sides of the 
tablets using the tablet holder. The Raman activity of tablets showed to depend on the 
formulation type and mixture of excipients used. Key differences were seen in the 
Raman activity between authentic and counterfeit tablets (Table 1).  
Authentic clopidogrel tablets (clopidogrel B1, B2, B3 and B5) showed medium or 
strong Raman activity in contrary to the counterfeit tablets that had weak Raman 
activity. The authentic clopidogrel tablets had shorter exposure time between 0.22-
0.25 seconds that was required to take 3-4 scans/spectrum. The authentic tablets also 
showed 8-12 characteristic peaks, Raman intensities in the range of 2684.9 – 5082 
arbitrary units and S/N in the range of 2.57-29.9 arbitrary units. Nonetheless, the 
counterfeit clopidogrel tablets showed longer exposure time of 0.75 seconds that was 
required to take one scan/spectrum only. Both counterfeit tablets showed 12 
characteristic peaks and intensities around 5000 arbitrary units; however, they had 
differences in S/N. The second counterfeit batch’s spectrum (clopidogrel B6) showed 
more noise that the first (S/N = 3.85).  
Levothyroxine tablets evaluated were all authentic and contained the same list of 
excipients. Subsequently, the Raman activity of the evaluated batches was medium 
or strong. All the four batches showed around 0.7 seconds exposure time to collect 
two scans/spectrum. The aforementioned batches showed 27 characteristic peaks, 
Raman intensities in the range of 7023.6-7127.4 arbitrary units and S/N in the range 
of 8.8-22. It is notable to mention that levothyroxine B4 showed a significantly high 
S/N to other batches, which could be attributed to less noise in batch’s spectra.  
 
Capsules 
Raman signatures of capsules could not be obtained through the gelatin material. 
Subsequently, capsule contents were emptied into glass vials and the Raman 
signatures of the capsules were measured through glass vials using the vial holder. 
All the evaluated capsules were authentic and showed similar Raman activity for each 
medicine (Table 1). Overall, the capsules’ content required longer exposure times than 
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tablets despite the presence of similar excipients. This could be attributed to the 
formulation type.  
Orlistat batches (B1 – B6) showed 1.5 seconds exposure time required to collect two 
scans/spectrum. Despite taking longer times to scan, the aforementioned batches 
showed medium Raman activity with 25 characteristic peaks per spectrum over the 
wavenumber range of 300 – 3200 cm-1, and maxima Raman intensities in the range 
of 10943.6 – 13665.9 arbitrary units. Yet, the noise in the spectra was high (S/N 
around 2-3) and this contributed to the medium Raman activity of the batches. 
Sibutramine batches (B1-B6) showed better Raman activity (strong) than orlistat 
batches despite requiring similar exposure times. Sibutramine batches had 1.4 
seconds exposure time for collection of two scans/spectrum. However, they showed 
more characteristic peaks (n = 31) compared to orlistat batches. Also, sibutramine 
batches showed higher S/N ratios (between 10.7 and 16.9) despite having lower 
maxima intensities (between 9134.3 and 9916.6 arbitrary units).   
 
Gels 
Gel- (semisolid) formulations used showed weaker Raman activity than powders, 
tablets and capsules. Exposure times varied between diverse batches of the same 
medicine and that could be attributed to difference in both constituents and 
formulation. Hence, the three ibuprofen gels evaluated showed exposure times of 2.1, 
1.8 and 3.1 respectively (Table 1). The number of characteristic peaks for the 
aforementioned three formulations were 8, 12 and 10, and the maxima intensities were 
3712.6, 3701.6 and 3686.3 respectively. The gel (ibuprofen B2) with the least 
exposure time showed better spectral quality than the other two batches. Hence, 
ibuprofen B2 showed higher S/N (of 8.28) despite having close maximum Raman 
intensity that was 3701.6 arbitrary units. 
Less differences were seen between the spectra; of diclofenac gel batches (B1-B5), 
which showed shorter exposure times than ibuprofen batches. Exposure times for 
diclofenac batches were in the range of 0.25 – 2.67 seconds. The batch with the 
longest exposure time (i.e. diclofenac B5) showed the lowest number of characteristic 
peaks (n = 11) and S/N of 5.7 despite a high intensity of 6278.9 arbitrary units. 
Likewise, batches with exposure times of around one second (B1 and B2) showed 
characteristic peaks of 17 and 13 respectively. B1 had better spectral quality than B5 
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and B2 due to the low noise attributed in the spectra. Batches with shorter exposure 
times (B3 and B4) showed 20 and 21 peaks respectively. Therefore, increased noise 
in the gels’ spectra was featured with longer exposure times. 
 
Liquids 
Similarly, liquids with longer exposure times showed noisier spectra (Table 1). For 
instance, cough mixture B1 showed exposure time of 3.1 seconds, nine peaks and 
S/N = 5.91. Cough mixture B2 showed slightly less exposure time (2.5 seconds) that 
corresponded to higher S/N (8.32). The number of peaks for the aforementioned 
formulation was 16. On the other hand, cough mixture B3 showed the shortest 
exposure time (1.7 seconds) and better spectral quality among the cough mixtures. 
Thus, cough mixture B3 showed 18 characteristic peaks and S/N of 24.4.    
 
Authentication 
The signatures of medicines are proportional to the Raman active substance(s) 
present in these medicines [6,7].  Therefore, linear classification algorithms including 
CWS and PCA have proved successful in previous work for identifying pharmaceutical 
powders and tablets [7-9, 14]. Yet, the accuracy of this approach was not evaluated 
for liquids and semisolids; or for closely related substances. So, both methods were 
evaluated in this work for identifying the different formulations measured; taking both 
type I and type II errors into account.  
For CWS method, Type I errors were encountered when an authentic substance gave 
an r value < 0.95 against the spectra of the same substance/material.  Type II error 
was encountered when a substance/formulation gave an r value > 0.95 for different 
material.  When the excipients were evaluated, type I error was observed among the 
Raman spectra of microcrystalline cellulose and sodium carboxymethylcellulose 
(Figure 2). This could be attributed to fluorescence encountered in both samples’ 
spectra between 1800 and 2500 cm-1. Remarkably, no type II errors were observed 
between the different excipients. Likewise, no type II errors was observed among 
tablets spectra and only type I error was observed with counterfeit clopidogrel (B4 and 
B6) tablets’ spectra. Capsules showed only type I error among orlistat batches’ spectra 
but not sibutramine tablets’ spectra. On the other hand, only type II errors were 
observed with spectral comparison of liquids and gels. This could be partly due to the 
 9 
overlapping constituents among the different formulations and to the low Raman 
activity compared to powders. 
 
 
Figure 2. Correlation map of the raw Raman spectra of lactose (1-20), 
magnesium stearate (21-40), microcrystalline cellulose (41-60), sucrose (61-80), 
sodium carboxymethylcellulose (81-100) and titanium dioxide (101-120) 
measured using a handheld dual laser Raman spectrometer. The colour bar on 
the left shows the range of r values between 0 (blue) and 1 (dark red). Blue colour 
indicates 0-0.3, green 0.30.5, yellow 0.5-0.6, orange 0.7-0.9 and red above 0.9. 
 
Subsequently, PCA was applied to the Raman spectra of different formulations 
including powders, tablets, capsules, gels and liquids. Type I error was observed in 
PC scores when a substance’s score was not clustered among its reference scores, 
or when an authentic medicine’s score was not clustered among the additional 
authentic medicines’ score. Moreover, type II error was seen when a substance’s 
score was clustered among the scores of different substances, or when a counterfeit 
medicine’s score was clustered among the authentic scores.  
PCA showed to be a more accurate and precise technique than CWS as it investigated 
variance among the spectra provided [17]. In this respect, PC1 corresponded to the 
highest variance among the spectra, PC2 to the second highest variance not related 
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to PC1 and so on. With this approach, noise in spectra did not show significant 
interference with the accuracy of identification. Figure 3 shows the PC scores of the 
Raman spectra of the six excipients evaluated with no type I and type II errors. The 
scores in the aforementioned case contributed to 95.1% of the variance among the 
data. The scores plot showed a clear differentiation between the five excipients. Two 
scores showed clusters near each other (microcrystalline cellulose and sodium 
carboxymethylcellulose), and that was attributed to similarity in their chemical 
signatures and Raman scattering (Figure 1).  
 
 
Figure 3. PCA scores plot of the raw Raman spectra of lactose (blue), 
magnesium stearate (green), microcrystalline cellulose (red), sodium 
carboxymethylcellulose (magenta), sucrose (cyan) and titanium dioxide (black) 
measured using a handheld dual laser Raman spectrometer. 
 
Hence, PCA was successful in authenticating the different formulations despite the 
presence of low APIs within the formulations. For instance, the PC scores of authentic 
and counterfeit clopidogrel tablets were clearly clustered with no overlaps (Figure 4). 
The counterfeit tablets showed two distinct clusters that could be attributed to the 
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manufacturing source. Likewise, the PC scores of levothyroxine reference and test 
tablets were clustered together (with the exception of one score) and this attributed to 
the same manufacturing source (Figure 4). 
 
 
Figure 4. PCA scores plot of the raw Raman spectra of (a) authentic (blue) and 
test (red) clopidogrel (left), and levothyroxine measured using a handheld dual 
laser Raman spectrometer. 
 
Conclusion 
Handheld Raman spectroscopy offered a rapid technique for authenticating different 
medicine formulations. The results showed that the Raman signatures of the 
investigated samples could be collected in less than four seconds. The Raman 
signatures did not only depend on the Raman active substances and their 
concentrations; but also, on the formulation type and physical properties of the 
materials measured. The spectral quality was an important factor to be taken into 
account when authenticating medicines. Noise was seen as a key factor that interfered 
with the Raman signatures of medicines and thus gave type I/type II errors when using 
the CWS algorithm. PCA algorithm was successful in overcoming issues associated 
with noise but showed overlap among substances of similar chemical structures. 
Therefore, future approach to medicines’ authentication should take into account 
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